PHRM SCI - ADME PART 1
Course Expectations and Assessment Strategy
Exam Performance and Learning Guidance:
The average score on the first examination set the highest historical record for this course.
Exam 2 Characteristics: Exam 2 is designed to test deep conceptual understanding and integrative reasoning rather than simple calculation or recall.
Study Strategy: Regular, daily review of lecture and textbook notes is essential to build intuitive problem-solving skills.
Evolution of Exam Question Types:
Exam 1 typical question: Direct calculation of the extent to which a drug is ionized at a specific .
Exam 2 typical question: Comparative physiological outcomes (e.g., given two drug structures, predicting which will exhibit a superior oral absorption profile, or which will be eliminated renally at a faster or slower rate).
Model Drug Properties for Acid-Base Calculations
Structural Parameters of the Model Drug:
Chemical Class: Quinoline derivative (containing a basic pyridine-like nitrogen).
Neutral Groups: All other nitrogen atoms within the structure are non-basic/neutral.
Acid-Base Parameter: Acid dissociation constant for the single basic group.
\text{Drug-H}^+ \rightleftharpoons \text{Drug} + \text{H}^+ \tag{pKa = 4.0}
Cellular Membranes and Transport Mechanisms
Cellular Classification for Membrane Crossing:
Whenever evaluating drug transport across a biological barrier, the specific cell type forming the membrane must be identified:
Epithelial Cells:
Line all body compartments and surfaces exposed to the external environment.
Locations: Gastrointestinal (GI) tract lumen, urinary tract, kidney tubules.
Mechanism: Crossing from the GI tract into blood, or reabsorbing from renal tubules back into blood, occurs across epithelial layers.
Endothelial Cells:
Line internal body compartments not exposed to the outside world (e.g., vascular blood vessel walls).
Mechanism: Transport across endothelial layers follows capillary leakage dynamics rather than simple transcellular lipid bilayer permeation.
Mechanisms of Transmembrane Movement:
Simple Passive Diffusion:
Primary pathway for most orally administered small-molecule drugs.
Driven purely by the concentration gradient (movement from high concentration to low concentration).
Operates without energy input or adenosine triphosphate () consumption.
Directionality: Unidirectional down the concentration gradient, guaranteeing net forward movement from the gut lumen into the cytosol, into blood, and ultimately into tissue sites containing target proteins.
Active Transport:
Movement of molecules against a concentration gradient.
Strictly requires direct energy expenditure via hydrolysis.
Physicochemical Requirements for Oral Passive Diffusion:
Log P Target Range:
Ideal partition coefficient range for orally bioavailable drugs: .
Mechanistic progression: The drug must be sufficiently hydrophilic to associate via intermolecular forces with polar phospholipid head groups, squeeze through the outer membrane layer, interact comfortably with nonpolar hydrocarbon fatty acyl tail groups in the bilayer interior, and reverse the process to exit into the cytosol.
Molecular Weight ():
Optimal molecular weight for small-molecule oral absorption: .
Biologics/Proteins: Exceed molecular weight thresholds and cannot absorb via passive diffusion; must be administered via parenteral injection (though research into forced intestinal engulfment/endocytosis continues).
Ionization State Constraints:
Phospholipid bilayers possess nonpolar interior core tails composed strictly of carbon and hydrogen atoms.
Charged (ionized) molecules (e.g., dissociated salts like ) cannot dissolve in or cross this hydrophobic core without a dedicated transport vesicle.
Fundamental Rule: Only the nonionized form of a drug can undergo simple passive diffusion across a lipid bilayer.
Compartmental Acid-Base Dynamics and Percentage Calculations
Stomach Environment
Physiological Parameters:
Fasted stomach .
Model drug basic
Ionization Balance:
Ambient (environment is proton-rich relative to drug site).
Predominant Form: Protonated/Ionized conjugate acid ().
Form Distribution: , .
Solubility vs. Absorption in Stomach:
Dissolution: High percentage of ionization () imparts significant polarity, promoting high drug dissolution in gastric fluid (assuming no enteric protective coating).
Absorption: Zero/negligible absorption occurs in the stomach.
Reason 1: Nonionized fraction is extremely minute ().
Reason 2: The stomach architecture lacks the necessary microvilli folds and surface area required for drug absorption.
Course Rule: Assume absorption in the stomach for all clinical and analytical scenarios.
Small Intestine Environment
Physiological Parameters:
Small intestine
Model drug basic
Ionization Balance:
Ambient (environment causes proton loss from the basic conjugate acid).
Predominant Form: Deprotonated/Nonionized free base ().
Form Distribution: , .
Solubility vs. Absorption in Small Intestine:
Solubility: Low water solubility due to minimal ionization ().
Absorption/Permeability: Extremely high absorption rate driven by the predominant nonionized form ().
Anatomical Suitability: Extensive length and microscopic finger-like projections (villi/microvilli) provide huge surface area for passive absorption.
Pharmaceutical Solubility Standards & Equilibrium Principles
Chemical vs. Pharmaceutical Definition of Dissolution:
Classical/Chemical Solubility: Complete dissolution resulting in an entirely clear liquid phase.
FDA/Pharmaceutics Standard: Defined as at least of drug substance dissolving per (or ) of water. Complete solution clarity is not required for absorption to proceed.
Le Chatelier's Principle in Drug Absorption:
In the GI tract, ionized and nonionized forms exist in dynamic chemical equilibrium:
While only the nonionized form () crosses the intestinal epithelial wall, its removal via passive diffusion continuously depletes the right side of the equilibrium.
By Le Chatelier's Principle, the system shifts rightward to re-establish the equilibrium ratio dictated by the local .
This continuous equilibrium shift allows initially undissolved or ionized drug fractions to progressively convert to the nonionized form and absorb completely over time.
Structure-Activity Relationships, Single Isomers, and Safety
Log P, Permeability, and Bioavailability Trends:
Increasing a molecule's generally enhances membrane permeability and rate of oral absorption.
Historically, pharmaceutical developers artificially increased compound potency by elevating to maximize fraction absorbed (bioavailability).
Regulatory and Safety Implications of Excessive Lipophilicity:
Extremely lipophilic drugs cannot be eliminated directly by the kidneys in their native state because renal tubule reabsorption returns them to circulation.
High drugs strictly require hepatic clearance via oxidative metabolism to form polar metabolites.
Required hepatic metabolism drastically increases the risk of Drug-Drug Interactions (DDIs) due to competitive inhibition or induction of metabolic enzymes (e.g., Cytochrome P450 systems).
Racemic Mixtures vs. Single Enantiomer Drug Development:
Chiral Switching Strategy: Developing a single pure enantiomer near the patent expiration of a racemic drug mixture (e.g., Omeprazole [Prilosec, mixture] to Esomeprazole [Nexium, -isomer]).
Case Study - Sildenafil (Viagra):
Marketed originally as a racemic mixture of isomers.
Near patent expiration, attempts were made to bring the single active isomer to market.
Outcome: Clinical trials failed because the isolated single isomer induced severe toxicity and side effects that were muted or unobserved in the isomeric mixture.
Clinical Polypharmacy and Pharmacist Responsibilities
Deprescribing and Polypharmacy Hazards:
Patients in long-term care or complex clinical settings are frequently prescribed concurrent medications.
Prescribing Cascade: Occurrence where Drug A produces an adverse side effect Drug B is prescribed to treat the side effect Drug B causes a new side effect Drug C is added.
Administering tens of foreign small molecules into systemic circulation inevitably induces unmonitored metabolic and pharmacodynamic interactions.
Clinical Deprescribing Outcome: Terminal or geriatric patients systematically removed from non-essential drugs